Drug Royalties Stocks
Companies whose revenue is mainly royalties on drugs other companies sell -- the royalty buyers and platform licensors, not drug developers that also earn some.
As of Oct 30, 2026, Drug Royalties has 7 US-listed companies worth $62.9B combined. The median member moved +4.2% over the past week; OABI led at +9.7% and TXMD trailed at +0.0%.
Companies in Drug Royalties
- RPRX – Royalty Pharma Plc, $37.5B
- HALO – Halozyme Therapeutics Inc, $14.8B
- LGND – Ligand Pharmaceuticals Incorporated, $6.3B
- ZYME – Zymeworks Inc. Common Stock, $2.1B
- INVA – Innoviva Inc, $1.5B
- OABI – OmniAb Inc., $760M
- TXMD – TherapeuticsMD Inc, $23.8M